Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bausch & Lomb Corp (BLCO)

Bausch & Lomb Corp (BLCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,597,680
  • Shares Outstanding, K 351,834
  • Annual Sales, $ 4,146 M
  • Annual Income, $ -260,000 K
  • 60-Month Beta 0.46
  • Price/Sales 1.35
  • Price/Cash Flow 8.32
  • Price/Book 0.85
Trade BLCO with:

Options Overview Details

View History
  • Implied Volatility 27.78% ( +4.28%)
  • Historical Volatility 38.39%
  • IV Percentile 12%
  • IV Rank 19.62%
  • IV High 107.01% on 09/15/23
  • IV Low 8.45% on 09/07/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 53
  • Volume Avg (30-Day) 195
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 5,406
  • Open Int (30-Day) 5,887

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.16
  • Number of Estimates 8
  • High Estimate 0.19
  • Low Estimate 0.13
  • Prior Year 0.22
  • Growth Rate Est. (year over year) -27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.27 +4.19%
on 08/14/24
16.75 -5.01%
on 09/03/24
-0.03 (-0.19%)
since 08/06/24
3-Month
14.05 +13.24%
on 07/24/24
17.85 -10.87%
on 08/01/24
+0.43 (+2.78%)
since 06/06/24
52-Week
13.16 +20.90%
on 05/02/24
17.92 -11.19%
on 09/12/23
-1.78 (-10.06%)
since 09/06/23

Most Recent Stories

More News
Bausch + Lomb: Q2 Earnings Snapshot

Bausch + Lomb: Q2 Earnings Snapshot

BLCO : 15.91 (+0.13%)
This Bausch Health Companies Unusually Active Option Is a No-Brainer

Bausch Health Companies had the 8th-highest Vol/OI ratio in Wednesday trading. The pharmaceutical company’s unusual options activity suggests it might have more gains ahead.

BHC : 6.21 (+0.32%)
BLCO : 15.91 (+0.13%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

OKYO : 1.0200 (-2.86%)
ALC : 94.66 (+0.26%)
BLCO : 15.91 (+0.13%)
JNJ : 164.38 (-0.37%)
RHHBY : 40.4900 (-0.37%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

/PRNewswire/ -- The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome...

OKYO : 1.0200 (-2.86%)
ALC : 94.66 (+0.26%)
BLCO : 15.91 (+0.13%)
JNJ : 164.38 (-0.37%)
RHHBY : 40.4900 (-0.37%)
Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better,...

BLCO : 15.91 (+0.13%)
BLCO.TO : 21.53 (+0.23%)
Bausch + Lomb Releases Annual Environmental, Social and Governance Report

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better,...

BLCO : 15.91 (+0.13%)
BLCO.TO : 21.53 (+0.23%)
Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 podium...

BLCO : 15.91 (+0.13%)
BLCO.TO : 21.53 (+0.23%)
Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election...

BLCO : 15.91 (+0.13%)
BLCO.TO : 21.53 (+0.23%)
Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™...

BLCO : 15.91 (+0.13%)
BLCO.TO : 21.53 (+0.23%)
Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of eight scientific...

BLCO : 15.91 (+0.13%)
BLCO.TO : 21.53 (+0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R)....

See More

Key Turning Points

3rd Resistance Point 16.35
2nd Resistance Point 16.16
1st Resistance Point 16.04
Last Price 15.91
1st Support Level 15.73
2nd Support Level 15.54
3rd Support Level 15.42

See More

52-Week High 17.92
Fibonacci 61.8% 16.10
Last Price 15.91
Fibonacci 50% 15.54
Fibonacci 38.2% 14.98
52-Week Low 13.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar